-
EP4125848
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4125848
| EP4125848 - CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 06.01.2023 Database last updated on 02.11.2024 | |
| Former | The international publication has been made Status updated on 02.10.2021 | ||
| Former | unknown Status updated on 31.03.2021 | Most recent event Tooltip | 03.04.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Dompe' Farmaceutici SpA Via Santa Lucia 6 20121 Milano / IT | [2023/06] | Inventor(s) | 01 /
ALLEGRETTI, Marcello c/o DOMPE' FARMACEUTICI SPA Via Campo di Pile, snc. 67100 L'AQUILA / IT | 02 /
MANTELLI, Flavio c/o DOMPE' FARMACEUTICI SPA Via Campo di Pile, snc. 67100 L'AQUILA / IT | 03 /
PIEMONTI, Lorenzo San Raffaele Scientific Institute Via Olgettina 60 20132 MILANO / IT | [2023/06] | Representative(s) | Dompé farmaceutici Spa Via San Martino, 12-12/a 20122 Milano / IT | [N/P] |
| Former [2023/06] | Mauri, Elisabetta Maria Ester Dompé Farmaceutici S.p.A. Via Santa Lucia, 6 20122 Milano / IT | Application number, filing date | 21713677.9 | 24.03.2021 | [2023/06] | WO2021EP57624 | Priority number, date | EP20200166073 | 26.03.2020 Original published format: EP 20166073 | EP20200211370 | 02.12.2020 Original published format: EP 20211370 | [2023/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021191305 | Date: | 30.09.2021 | Language: | EN | [2021/39] | Type: | A1 Application with search report | No.: | EP4125848 | Date: | 08.02.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.09.2021 takes the place of the publication of the European patent application. | [2023/06] | Search report(s) | International search report - published on: | EP | 30.09.2021 | Classification | IPC: | A61K31/18, A61K31/426, A61P11/00, A61P31/14, A61K31/167, A61K31/431, A61K31/496, A61K31/546, A61K31/573, A61K31/616, A61K31/635, A61K31/7052, A61K31/706, A61K31/727, A61K38/20, A61K45/06 | [2023/06] | CPC: |
A61P11/00 (EP,IL);
A61K31/18 (EP,IL,US);
A61K31/135 (US);
A61K31/167 (EP,IL,US);
A61K31/415 (US);
A61K31/426 (EP,IL);
A61K31/431 (EP,IL,US);
A61K31/496 (EP,IL,US);
A61K31/546 (EP,IL,US);
A61K31/573 (EP,IL,US);
A61K31/616 (EP,IL,US);
A61K31/635 (EP,IL,US);
A61K31/675 (US);
A61K31/7052 (EP,IL,US);
A61K31/706 (EP,IL);
A61K31/727 (EP,IL);
A61K31/737 (US);
A61K38/2006 (US);
| C-Set: |
A61K31/167, A61K2300/00 (EP);
A61K31/18, A61K2300/00 (EP);
A61K31/426, A61K2300/00 (EP);
A61K31/431, A61K2300/00 (EP);
A61K31/496, A61K2300/00 (EP);
A61K31/546, A61K2300/00 (EP);
A61K31/573, A61K2300/00 (EP);
A61K31/616, A61K2300/00 (EP);
A61K31/635, A61K2300/00 (EP);
A61K31/7052, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/06] | Title | German: | CXCL8-INHIBITOREN ZUR VERWENDUNG BEI DER BEHANDLUNG VON COVID-19 | [2023/06] | English: | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | [2023/06] | French: | INHIBITEURS DE CXCL8 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA COVID-19 | [2023/06] | Entry into regional phase | 13.09.2022 | National basic fee paid | 13.09.2022 | Designation fee(s) paid | 13.09.2022 | Examination fee paid | Examination procedure | 13.09.2022 | Examination requested [2023/06] | 13.09.2022 | Date on which the examining division has become responsible | 28.04.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 31.03.2023 | Renewal fee patent year 03 | 31.03.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IY]WO0205814 (SMITHKLINE BEECHAM CORP [US], et al) [I] 1-8,16 * claims 1-13 * * page 3, lines 12-28 * * page 4, line 1 - page 5, line 22 * * Results; page 13 - page 15 * [Y] 1-16; | [IDY]WO2005090295 (DOMPE SPA [IT], et al) [ID] 1-6,8-11,16 * the whole document * [Y] 1-11,16; | [IDY]WO2007135080 (DOMPE PHA R MA SPA RES & MFG [IT], et al) [ID] 1-6,8,14-16 * the whole document * [Y] 1-8,14-16; | [IDY]WO2010031835 (DOMPE SPA [IT], et al) [ID] 1-6,8,12,13,16 * the whole document * [Y] 1-8,12,13,16; | [IY]EP2316820 (DOMPE SPA [IT]) [I] 1-6,8,12,13,16 * compounds of the table, in particular 21-22 and 78 * * paragraph [0020] * * claims 1-16 * [Y] 1-8,12,13,16; | [IY]EP3409277 (DOMPE FARM SPA [IT]) [I] 1-6,8-13,16 * claims 1-17 * * see experimental section; column 13 - column 19 * [Y] 1-16; | [XPY]CN111378008 (SOUTH CHINA SEA INST OCEANOLOGY CAS) [XP] 1-6,8,16 * claim 1; tables 2-3 * * Preferably, the antiviral drug is an anti-COVID-19 virus drug. The present invention is separated and purified from recombinant strains to obtain antiviral activity, especially having inhibitory activity on the 3CL hydrolase of the novel coronavirus, and is expected to be used in the preparation of antiviral drugs. * [Y] 1-16; | [XPY]CN111701015 (EIJING YISITENG TRANSLATION SERVICE CO LTD) [XP] 1-6,8,16 * examples 1-4; claims 1-5 * [Y] 1-16; | [XY] - Miguel Angel Martinez, "Compounds with therapeutic potential against novel respiratory 2019 coronavirus", Antimicrobial agents and chemotherapy, United States, doi:10.1128/aac.00399-20, (20200309), URL: https://aac.asm.org/content/aac/64/5/e00399-20.full.pdf, (20200909), XP055729045 [X] 1-6,8,16 * For example, the serine protease inhibitor camostat mesylate inhibits the enzymatic activity of TMPRSS2 (44). Moreover, the clinically proven serine protease inhibitor camostat mesylate, which is active against TMPRSS2, partially blocked SARS-CoV-2 spike-driven entry into Caco-2 and Vero-TMPRSS2 cells (46). * * page 5 * [Y] 1-16 DOI: http://dx.doi.org/10.1128/aac.00399-20 | [ ] - HOFFMANN MARKUS ET AL, "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor", CELL, ELSEVIER, AMSTERDAM NL, vol. 181, no. 2, doi:10.1016/J.CELL.2020.02.052, ISSN 0092-8674, (20200305), page 271, (20200305), XP086136225 [ ] * The Cellular Serine Protease TMPRSS2 Primes SARS-2-S for Entry, and a Serine Protease Inhibitor Blocks SARS-CoV-2 Infection of Lung Cells; pages 273-274 * DOI: http://dx.doi.org/10.1016/j.cell.2020.02.052 | [IY] - ZARBOCK A ET AL, "Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice : CXCR2 inhibitor protects against ALI", UK, vol. 155, no. 3, doi:10.1038/bjp.2008.270, ISSN 0007-1188, (20081001), pages 357 - 364, BRITISH JOURNAL OF PHARMACOLOGY, URL: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1038%2Fbjp.2008.270, XP055792870 [I] 1-6,8-16 * the whole document * [Y] 1-16 DOI: http://dx.doi.org/10.1038/bjp.2008.270 | [Y] - Qin Chuan ET AL, "Dysregulation of immune response in patients with COVID-19 in Wuhan, China", Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, US, doi:10.1093/cid/ciaa248, (20200312), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108125/pdf/ciaa248.pdf, (20210407), XP055793239 [Y] 1-16 * the whole document * DOI: http://dx.doi.org/10.1093/cid/ciaa248 | [IPY] - Anonymous, "Announces Italian Authorization of Phase 2/3 Clinical Trial of Dompé's Reparixin for the Treatment of Severe Patients with COVID- 19 Pneumonia", (20200512), URL: https://www.dompe.us/media/press-releases/aifa-announces-italian-authorization-of-phase-2-3-clinical-trial-of-domp%C3%A9s-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia, (20210407), XP055793011 [IP] 1-6,8-16 * the whole document * [Y] 1-16 | [IPY] - Anonymous, "Clinical study Protocol - Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia", (20200512), URL: https://www.dompe.us/media/press-releases/aifa-announces-italian-authorization-of-phase-2-3-clinical-trial-of-domp%C3%A9s-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia, (20210407), XP055793016 [IP] 1-6,8-16 * 2.Introduction; pages 10-14 * * Phase 2/3 study endpoints; page 15 * [Y] 1-16 | [IPY] - Anonymous, "Agenzia Italiana del Farmaco - MODULO DI COMUNICAZIONE AL RICHIEDENTE, AGLI ALTRI COMITATI ETICI E AD AIFA DELLA DECISIONE DEL COMITATO ETICO RELATIVA AL PARERE UNICO", (20200512), URL: https://www.dompe.us/media/press-releases/aifa-announces-italian-authorization-of-phase-2-3-clinical-trial-of-domp%C3%A9s-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia, (20210407), XP055793029 [IP] 1-6,8-16 * the whole document * [Y] 1-16 | [IPY] - Anonymous, "Reparixin in COVID-19 Pneumonia - Efficacy and Safety - NCT04794803", (20210316), URL: https://clinicaltrials.gov/ct2/show/NCT04794803, (20210407), XP055792998 [IP] 1-6,8-16 * the whole document * [Y] 1-16 | [XPY] - MARKUS HOFFMANN ET AL, "Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, US, (20200420), vol. 64, no. 6, doi:10.1128/AAC.00754-20, ISSN 0066-4804, XP055732029 [XP] 1-6,8,16 * whole document, in particular "Nafamostat, a structural analog of Camostat, blocks SARS-CoV-2 infection of human lung cells with 15-fold higher efficiency than Camostat mesylate; this makes it a good compound to enter clinical trials for COVID-19 treatment [20]" * [Y] 1-16 DOI: http://dx.doi.org/10.1128/AAC.00754-20 | [XPY] - JAFARI RAMEZAN ET AL, "Large saddle pulmonary embolism in a woman infected by COVID-19 pneumonia", GB, vol. 41, no. 22, doi:10.1093/eurheartj/ehaa402, ISSN 0195-668X, (20200506), pages 2133 - 2133, EUROPEAN HEART JOURNAL, URL: http://academic.oup.com/eurheartj/article-pdf/41/22/2133/33368365/ehaa402.pdf, XP055793174 [XP] 1-8,16 * the whole document * [Y] 1-16 DOI: http://dx.doi.org/10.1093/eurheartj/ehaa402 | [XPY] - XIAOXING CHEN ET AL, "The coronavirus diseases 2019 (COVID-19) pneumonia with spontaneous pneumothorax: a case report", BMC INFECTIOUS DISEASES, BIOMED CENTRAL LTD, LONDON, UK, (20200909), vol. 20, no. 1, doi:10.1186/S12879-020-05384-X, pages 1 - 5, XP021281454 [XP] 1-6,8,16 * the whole document * [Y] 1-16 DOI: http://dx.doi.org/10.1186/s12879-020-05384-x | [Y] - WANG MANLI ET AL, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", CELL RESEARCH,, vol. 30, no. 3, doi:10.1038/S41422-020-0282-0, ISSN 1001-0602, (20200204), pages 269 - 271, (20200204), XP037049320 [Y] 1-16 * the whole document * DOI: http://dx.doi.org/10.1038/s41422-020-0282-0 | [YP] - ALKOTAJI MYASAR, "Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER, AMSTERDAM, NL, vol. 56, no. 6, doi:10.1016/J.IJANTIMICAG.2020.106192, ISSN 0924-8579, (20201010), (20201010), XP086367962 [YP] 1-16 * the whole document * DOI: http://dx.doi.org/10.1016/j.ijantimicag.2020.106192 | by applicant | WO0024710 | WO2005090295 | WO2007135080 | WO2010031835 | - "Viruses of Vertebrates", PEREIRA, H et al., Coronaviridae, (19890000), pages 42 - 57 | - HOLMES, K.V. et al., Virology, (19960000), vol. 1, pages 1075 - 1093 | - MIN et al., Sci Rep, (20160000), vol. 6, page 25359 | - CHANNAPPANAVAR et al., Semin Immunopathol, (20170000), vol. 39, no. 5, pages 529 - 539 | - YAN CUI et al., Environmental Health, (20030000), vol. 2, no. 1, page 15 | - LIYAO YANG, Front Cell Dev Biol, (20200000), vol. 8, page 91 | - I-YIN CHENG et al., Int J Mol. Sci., (20200000), vol. 21, page 227 | - HOME et al., Am J Respir Crit Care Med, (20180000), vol. 198, no. 6, page 759 | - ZAMBROCK et al., Br J Pharmacol, (20080000), vol. 155, pages 357 - 364 | - MOORE et al., J Immunol., (20000000), vol. 164, pages 908 - 915 | - BAGGIOLINI, M., Immunol. Rev., (20000000), vol. 177, pages 5 - 7 | - JIE JACK, Expert Opinion Ther. Patents, (20010000), vol. 11, no. 12 | - CHAO J. et al., Bioorganic & Medicinal Chemistry Letters, (20070000), vol. 17, pages 3778 - 3783 | - BUSCH-PETERSEN, J. Current Topics in Medicinal Chemistry, (20060000), vol. 6, pages 1345 - 135 | - ALLEGRETTI et al., Immunology Letters, (20120000), vol. 145, pages 68 - 78 | - Remington's Pharmaceutical Science, Mack Publishing Company |